FHIR © HL7.org  |  FHIRsmith 0.14.2  |  Server Home  |  XIG Home  |  XIG Stats  | 

FHIR IG analytics

Packagede.medizininformatikinitiative.kerndatensatz.mtb
Resource TypeMedicationStatement
IdMedicationStatement-MTBChemo2MedicationStatement1.json
FHIR VersionR4

Resources that use this resource

No resources found


Resources that this resource uses

No resources found


Narrative

Note: links and images are rebased to the (stated) source


English


Generated Narrative: MedicationStatement MTBChemo2MedicationStatement1

basedOn: MedicationRequest: extension = 1,Predictive value of the biomarker or clinical effectiveness of the corresponding drug in a molecularly stratified cohort was demonstrated in a prospective study or a meta-analysis in the same tumor type.,http://doi.org#10.1200/JCO.2022.40.16_suppl.5512,http://www.ncbi.nlm.nih.gov/pubmed#38055253; status = completed; intent = proposal; medication[x] = MIRVETUXIMAB SORAVTANSINE; authoredOn = 2023-03-28

partOf: Procedure Chemotherapy

status: Completed

medication: MIRVETUXIMAB SORAVTANSINE

subject: Kim Musterperson (no stated gender), DoB: 1956-03-14

effective: 2023-06-24

note:

Z1 Mirvetuximab soravtansine 6mg/kg KG, Wdh d22

dosage

timing: Events: 2023-06-24

DoseAndRates

-Dose[x]
*6 mg/kg KG (Details: UCUM codemg/kg{KG} = 'mg/kg{KG}')

German


Generated Narrative: MedicationStatement MTBChemo2MedicationStatement1

basedOn: MedicationRequest: extension = 1,m1A,http://doi.org#10.1200/JCO.2022.40.16_suppl.5512,http://www.ncbi.nlm.nih.gov/pubmed#38055253; status = completed; intent = proposal; medication[x] = MIRVETUXIMAB SORAVTANSINE; authoredOn = 2023-03-28

partOf: Procedure Chemotherapy

status: Completed

medication: MIRVETUXIMAB SORAVTANSINE

subject: Kim Musterperson (no stated gender), DoB: 1956-03-14

effective: 2023-06-24

note:

Z1 Mirvetuximab soravtansine 6mg/kg KG, Wdh d22

dosage

timing: Events: 2023-06-24

DoseAndRates

-Dose[x]
*6 mg/kg KG (Details: UCUM codemg/kg{KG} = 'mg/kg{KG}')

Source1

{
  "resourceType": "MedicationStatement",
  "id": "MTBChemo2MedicationStatement1",
  "meta": {
    "profile": [
      "https://www.medizininformatik-initiative.de/fhir/core/modul-medikation/StructureDefinition/MedicationStatement"
    ]
  },
  "text": {
    "status": "generated",
    "div": "<!-- snip (see above) -->"
  },
  "basedOn": [
    {
      "reference": "MedicationRequest/mii-exa-mtb-medication-request-mirvetuximab"
    }
  ],
  "partOf": [
    {
      "reference": "Procedure/MTBChemo2Procedure"
    }
  ],
  "status": "completed",
  "medicationCodeableConcept": {
    "coding": [
      {
        "system": "http://fdasis.nlm.nih.gov",
        "code": "98DE7VN88D",
        "display": "MIRVETUXIMAB SORAVTANSINE"
      },
      {
        "system": "http://fhir.de/CodeSystem/bfarm/atc",
        "version": "2025",
        "code": "L01FX26",
        "display": "Mirvetuximab soravtansin"
      }
    ]
  },
  "subject": {
    "reference": "Patient/PatientKimMusterperson"
  },
  "effectiveDateTime": "2023-06-24",
  "note": [
    {
      "text": "Z1 Mirvetuximab soravtansine 6mg/kg KG, Wdh d22"
    }
  ],
  "dosage": [
    {
      "timing": {
        "event": [
          "2023-06-24"
        ]
      },
      "doseAndRate": [
        {
          "doseQuantity": {
            "value": 6,
            "unit": "mg/kg KG",
            "system": "http://unitsofmeasure.org",
            "code": "mg/kg{KG}"
          }
        }
      ]
    }
  ]
}